We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+0.01%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.47B
AUM Growth
+$68.2M
Cap. Flow
+$104M
Cap. Flow %
7.05%
Top 10 Hldgs %
50.84%
Holding
50
New
15
Increased
9
Reduced
8
Closed
8

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$85.6M
2
NUVA
NuVasive, Inc.
NUVA
+$51.4M
3
CI icon
Cigna
CI
+$41.4M
4
XRAY icon
Dentsply Sirona
XRAY
+$25.9M
5
PRGO icon
Perrigo
PRGO
+$23.4M

Top Sells

Rank Stock Value
1
AMAG
AMAG Pharmaceuticals
AMAG
+$55.7M
2
ABBV icon
AbbVie
ABBV
+$43.9M
3
BRKR icon
Bruker
BRKR
+$36.9M
4
CNMD icon
CONMED
CNMD
+$33.9M
5
MASI
Masimo
MASI
+$28.7M

Sector Composition

Rank Sector Weight
1 Healthcare 66.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DGX icon
26
Quest Diagnostics
DGX
$25.9B
$18.1M 1.23%
+250,000
New +$18.5M
OPCH icon
27
Option Care Health
OPCH
$3.36B
$16.9M 1.15%
1,162,500
+412,500
+55% +$6.98M
PLX icon
28
Protalix BioTherapeutics
PLX
$183M
$14.2M 0.97%
+727,458
New +$15.1M
VCYT icon
29
Veracyte
VCYT
$4.77B
$13.7M 0.93%
+1,226,994
New +$12.1M
ANGO icon
30
AngioDynamics
ANGO
$610M
$12.1M 0.82%
735,383
+6,900
+0.9% +$115K
DRRX
31
DELISTED
DURECT Corp
DRRX
$11.9M 0.81%
+500,000
New +$11.7M
ATXS
32
DELISTED
Astria Therapeutics
ATXS
$11.3M 0.77%
+15,460
New +$11.7M
EPRS
33
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
$10.5M 0.72%
1,847,500
– –
BIOL
34
DELISTED
Biolase, Inc.
BIOL
$9.28M 0.63%
427
-164
-28% -$4M
GNMK
35
DELISTED
GenMark Diagnostics, Inc
GNMK
$9.22M 0.63%
1,017,897
-464,765
-31% -$4.69M
NVTA
36
DELISTED
Invitae Corporation
NVTA
$7.44M 0.51%
500,000
+100,000
+25% +$1.42M
OSUR icon
37
OraSure Technologies
OSUR
$273M
$7M 0.48%
1,299,475
+435,252
+50% +$2.69M
KERX
38
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$4.99M 0.34%
500,000
-2,500,000
-83% -$26.8M
GYRE icon
39
Gyre Therapeutics
GYRE
$648M
$4.35M 0.3%
1,981
– –
CRDC
40
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$4.18M 0.28%
837,485
– –
BIOL
41
CALL
DELISTED
Biolase, Inc.
BIOL
$82K 0.01%
+147
New +$3.58M
ABBV icon
42
AbbVie
ABBV
$455B
– –
-750,000
Closed -$43.9M
BRKR icon
43
Bruker
BRKR
$9.79B
– –
-2,000,000
Closed -$36.9M
CNMD icon
44
CONMED
CNMD
$1.41B
– –
-670,943
Closed -$33.9M
INO icon
45
Inovio Pharmaceuticals
INO
$54M
– –
-20,833
Closed -$2.04M
TRVN
46
DELISTED
Trevena, Inc.
TRVN
– –
-4,592
Closed -$18.7M
MDRX
47
DELISTED
Veradigm Inc. Common Stock
MDRX
– –
-1,000,000
Closed -$12M
AMAG
48
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-1,018,246
Closed -$55.7M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Camber Capital Management held 50 positions worth $1.47B, up 4.9% from $1.4B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Camber Capital Management deployed $104M of net new capital in Q2 2015, opening 15 new positions and adding to 9 existing holdings. Its largest new stake was AstraZeneca: 1,250,000 shares worth $79.6M.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 62% a quarter earlier.

On the sell side, the largest reduction was Masimo, an estimated $28.7M trimmed.

  • Camber Capital Management's largest Q2 2015 buy was AstraZeneca: 1,250,000 shares worth $79.6M.
  • Camber Capital Management added most to CYBERONICS INC in Q2 2015, an estimated $15.7M increase.
  • Camber Capital Management's biggest Q2 2015 reduction was Masimo, cutting an estimated $28.7M.
  • Camber Capital Management fully exited AMAG Pharmaceuticals in Q2 2015, selling an estimated $55.7M.
  • Camber Capital Management's ten largest holdings make up 51% of its $1.47B portfolio in Q2 2015.
  • Camber Capital Management opened 15 new positions and closed 8 in Q2 2015.
  • Camber Capital Management's portfolio value rose 4.9% quarter-over-quarter to $1.47B.

Based on Camber Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.